PR.com: Business Directory, Press Releases, Jobs, Products, Services, Articles
 
Businesses Articles Press Releases Follow @PRcom
Press Release Pricing | News by Category | News by Country | News by US Region | Recent News | PR.com News on Your Site
 

Press Releases

 
Hematogenix

Press Release

Share      Blog

Receive press releases from Hematogenix: By Email PDF Version RSS Feeds:

Hematogenix Laboratory Services, LLC Announces the Availability of FDA Approved PD-L1 Companion Diagnostic Tests


Hematogenix Laboratory Services Announces the Availability of PD-L1 Companion Diagnostic Tests for KEYTRUDAŽ, Merck's Anti-PD-1 Therapy for Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 with Disease Progression on or after Platinum-Containing Chemotherapy as well as a PD-L1 Complementary Diagnostic Test to Support Bristol-Myers Squibb's OPDIVOŽ Anti-PD-1 Therapy for Non-Squamous Non-Small Cell Lung Cancer.

Tinley Park, IL, March 24, 2016 --(PR.com)-- Hematogenix Laboratory Services (Hematogenix), a leader in the field of integrated pathology services for drug development and clinical testing, announces the availability of the U.S. Food and Drug Administration (FDA) approved companion diagnostic assays, PD-L1 IHC 22C3 pharmDx and PD-L1 IHC 28-8 pharmDx. Both kits are available through Dako, an Agilent Technologies company.

Dako developed PD-L1 IHC 22C3 pharmDx in partnership with Merck & Co., Inc., maker of the anti-PD-1 therapy KEYTRUDA® (pembrolizumab). KEYTRUDA is approved by the FDA to treat patients with metastatic NSCLC whose tumors express PD-L1 as determined by the companion diagnostic assay and who have disease progression on or after platinum-containing chemotherapy.

PD-L1 IHC 28-8 pharmDx, also by Dako, was approved as a complementary diagnostic to detect PD-L1 protein expression levels and to help physicians determine which patients may benefit most from treatment with Bristol-Myers Squibb's OPDIVO® (nivolumab). OPDIVO® has extended indication, from melanoma and non-small cell lung cancer to renal cell cancer.

“The immuno-oncology agents Keytruda and Opdivo have already transformed the cancer care landscape,” said Hytham Al-Masri, M.D., CEO and Medical Director of Hematogenix. “The addition of these two tests to our already existing menu of PD-L1 assays helps to identify patients who may benefit from immunotherapy. With the availability of new companion diagnostics, we continue to see how immune therapies can benefit patients across a wide range of tumors.”

About Hematogenix
Hematogenix, is a CAP/CLIA certified laboratory with a full complement of board-certified clinical, anatomic and research pathologists to provide consultation and guidance for all aspects of their pharma and diagnostic services. The company offers a comprehensive array of biomarker development and testing services designed to navigate the complexities of human subject clinical trials. Hematogenix provides logistic management of tissue and sample procurement, distributes collection kits and contributes to standards and procedures required for initiating a clinical trial. Powered by a state-of-the-art laboratory information system, Hematogenix complies with rigorous chain-of-custody and specimen-management practices. Learn more about Hematogenix at www.hematogenix.com.
Contact Information
Hematogenix
Kathryn E. Evans
708-444-0444
Contact
www.hematogenix.com

Click here to view the list of recent Press Releases from Hematogenix
Promote Your Business